Apixaban no better than aspirin for preventing some strokes
February 08, 2024
February 08, 2024
ITHACA, New York, Feb. 8 -- Cornell University issued the following news:
More than a decade ago, the anticoagulant apixaban, trade name Eliquis, was shown to be superior to aspirin for preventing recurrent stroke in patients with a heart condition called atrial fibrillation.
But a multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atria . . .
More than a decade ago, the anticoagulant apixaban, trade name Eliquis, was shown to be superior to aspirin for preventing recurrent stroke in patients with a heart condition called atrial fibrillation.
But a multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atria . . .